News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
U.S. Panel Backs Dendreon Corporation’s Provenge for Medicare
November 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp's Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Vaccines
Kennedy Names New ACIP Members as Panel Quiets COVID-19 Vaccine Developers Ahead of Meeting
September 16, 2025
·
2 min read
·
Tristan Manalac
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
September 12, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Carves Tariff Exemptions for Some Pharma Products
September 12, 2025
·
2 min read
·
Tristan Manalac
China
Trump Reportedly Preparing Order Restricting Chinese Drug Licensing Deals
September 11, 2025
·
2 min read
·
Dan Samorodnitsky